A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer

Zahi Mitri, Cansu Karakas, Caimiao Wei, Brian Briones, Holly Simmons, Nuhad Ibrahim, Ricardo Alvarez, James L. Murray, Khandan Keyomarsi, Stacy Moulder

Research output: Contribution to journal › Article › peer-review

57 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences